Neurotech International Ltd has released a press release.
Phase I/II ASD Clinical Trials Results at 52 Weeks
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
In the deck
Earlier from Neurotech International
- First Patient Treated in Phase I/II PANDAS/PANS Trial
- Approval for Additional Phase I/II ASD Trial Extension
- HREC Approval for Phase I/II PANDAS/PANS Clinical Trial
- NTI Granted FDA Pre-IND Meeting for NTI164 in ASD
- Disclosure Document
Later from Neurotech International
- NTI to Launch Phase II Clinical Trial in Rett Syndrome
- NTI Completes Recruitment in PANDAS/PANS Clinical Trial
- NTI granted HREC Approval for PANDAS/PANS Trial Extension
- NTI Granted 2 Year Extension of Treatment for ASD Patients
- NTI Receives HREC Approval for Rett Syndrome Clinical Trial
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International